(Press-News.org) CHICAGO – Although botulinum toxin A ("Botox") injections are U.S. Food and Drug Administration approved for preventive treatment for chronic migraines, a review and analysis of previous studies finds a small to modest benefit for patients with chronic migraine headaches and chronic daily headaches, although botox injections were not associated with greater benefit than placebo for preventing episodic migraine or chronic tension-type headaches, according to an article in the April 25 issue of JAMA.
"Migraine and tension-type headaches are common. Although up to 42 percent of adults experience tension-type headaches sometime in their life, most do not seek medical advice. Migraines are less common, with a worldwide prevalence between 8 percent and 18 percent, but are associated with greater disability. Migraine headaches are responsible for $1 billion in medical costs and $16 billion in lost productivity per year in the United States alone," according to background information in the article. Botulinum toxin A injections were first proposed as headache treatment when it was observed that patients with chronic headaches receiving cosmetic botulinum injections experienced headache improvement, prompting several case series that suggested benefit. However, the medical literature on botulinum effectiveness for headaches has been mixed.
Jeffrey L. Jackson, M.D., M.P.H., of the Medical College of Wisconsin, Milwaukee, and colleagues performed a review and meta-analysis to assess the association of botulinum toxin A with reducing headache frequency when used for preventive treatment of migraine, tension, or chronic daily headaches in adults. For the study, headaches were categorized as episodic (less than 15 headaches per month) or chronic (15 or more headaches per month) migraine and episodic or chronic daily or tension headaches. The researchers identified 27 randomized placebo-controlled trials that included 5,313 study participants and 4 randomized comparisons with other medications that met study inclusion criteria.
Pooled analyses of the data suggested that botulinum toxin A was associated with fewer headaches per month among patients with chronic daily headaches (1,115 patients, -2.06 headaches per month) and among patients with chronic migraine headaches (1,508 patients, -2.30 headaches per month). There was no significant association between use of botulinum toxin A and reduction in the number of episodic migraine (1,838 patients, 0.05 headaches per month) or chronic tension-type headaches (675 patients, -1.43 headaches per month).
Compared with placebo, botulinum toxin A was associated with a greater frequency of blepharoptosis (drooping of the upper eyelid), skin tightness, paresthesias (a prickly, tingling sensation), neck stiffness, muscle weakness, and neck pain.
In the 4 trials that compared botulinum toxin A with other treatment modalities, botulinum toxin A was not associated with reduction in headache frequency compared with topiramate (1.4 headaches per month) or amitriptyline (2.1 headaches per month) for prophylaxis against chronic migraine headaches. "Botulinum toxin A was not associated with a reduction in headache frequency vs. valproate in a study of patients with chronic and episodic migraines (0.84 headaches per month) or in a study of patients with episodic migraines (0.3 headaches per month). Botulinum toxin A was associated with a greater reduction in average headache severity than methylprednisolone in a single trial among patients experiencing chronic tension-type headaches (-2.5 headaches per month)," the authors write.
"Our analyses suggest that botulinum toxin A may be associated with improvement in the frequency of chronic migraine and chronic daily headaches, but not with improvement in the frequency of episodic migraine, chronic tension-type headaches, or episodic tension-type headaches. However, the association of botulinum toxin A with clinical benefit was small. Botulinum toxin A was associated with a reduction in the number of headaches per month from 19.5 to 17.2 for chronic migraine and from 17.5 to 15.4 for chronic daily headaches."
###(JAMA. 2012;307[16]:1736-1745. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Neither Dr. Jackson nor Dr. Kuriyama has any conflicts to disclose. Although Dr. Hayashino has accepted speaker fees from a number of pharmaceutical firms, none of these manufacture botulinum toxin A.
To contact Jeffrey L. Jackson, M.D., M.P.H., call Maureen Mack at 414-955-4744 or email mmack@mcw.edu.
Botox injections associated with only modest benefit for chronic migraine and daily headaches
2012-04-25
ELSE PRESS RELEASES FROM THIS DATE:
Non-Drug Treatments for ADHD by Integrative Psychiatry Experts Dr. Richard P. Brown and Dr. Patricia Gerbarg is Released on Internet Bookseller Web Sites and in Bookstores by WW Norton
2012-04-25
Richard P Brown, MD, and Patricia Gerbarg, MD, Integrative Psychiatry experts, are authors of a new book with the latest complementary treatments for ADD/ADHD entitled Non-Drug Treatments for ADHD: New Options for Kids, Adults, & Clinicians (WW Norton, 2012, hardcover, 272 pages, ISBN 978-0-393-70622-2), now in release on Internet bookseller web sites, and in US and UK bookstores.
"This book is a winner! (It is) a lively, well-researched, hugely needed book on treatments for ADHD that do not involve the use of medication. In no way anti-medication, it addresses ...
Heart infection involving ICD associated with high rate of complications, risk of death
2012-04-25
CHICAGO – Patients with infective endocarditis involving implanted cardiac devices experience a high rate of complications such as valve infections, heart failure, and persistent bacteremia, and high in-hospital and 1-year mortality rates, particularly if there is valve involvement, according to a study in the April 25 issue of JAMA.
"Cardiac electronic devices, including permanent pacemakers and implantable cardioverter-defibrillators (ICDs), are increasingly implanted worldwide, with estimates of more than 4.2 million patients with a permanent pacemaker or ICD implanted ...
VLBW infants born at hospitals known for nursing excellence have better outcomes on some measures
2012-04-25
CHICAGO – In a study that included more than 72,000 very low-birth-weight infants, among those born in hospitals with recognition for nursing excellence (RNE), compared with non-RNE hospitals, there was a significantly lower rate of hospital infection, death at 7-days and severe intraventricular hemorrhage but not lower rates of death at 28-days or hospital stay mortality, according to a study in the April 25 issue of JAMA.
"One in 4 very low-birth-weight (VLBW) infants (less than 1,500 grams [3.3 lbs.]) dies in the first year of life; nearly all deaths (87 percent) occur ...
Watching and waiting is best management for pregnant women whose waters break early
2012-04-25
Pregnant women whose waters break late in preterm pregnancy but before they are in labor—the medical term for this situation is preterm prelabor rupture of the membranes—are best managed by monitoring and waiting until they deliver spontaneously rather than by inducing labor according to a study by Dutch researchers published in this week's PLoS Medicine.
In their study, David van der Ham, from the Maastricht University Medical Center, Netherlands, and colleagues randomized over 500 pregnant women with preterm prelabor rupture of the membranes between 34-37 weeks gestation ...
Many countries still lack a health research strategy
2012-04-25
Although there has been a steady increase in medical research from low- and middle- income countries in recent decades, there are still many countries that lack anything resembling a health research strategy, according to international experts writing in this week's PLoS Medicine.
In anticipation of the upcoming World Health Report on the need for health research, Martin McKee from the London School of Hygiene & Tropical Medicine, UK and colleagues make the case for the importance of establishing national health research strategies so that public health systems can function ...
Disclosure of financial conflicts of interest may worsen medical bias
2012-04-25
"Journals, professional associations, clinical guideline developers, and others need to worry not just that disclosure provides a band-aid to the real problem of the [conflict of interest] itself, but that any attempt to stem the trouble through disclosure policies may actually be worsening the problem," say the editors of PLoS Medicine writing in an editorial that discusses the response to a paper published in the Journal last month, which examined the financial conflicts of interest of members of the American Psychiatric Association (APA) responsible for updating the ...
Mayo Clinic identifies gene critical to development and spread of lung cancer
2012-04-25
JACKSONVILLE, Fla. — A single gene that promotes initial development of the most common form of lung cancer and its lethal metastases has been identified by researchers at Mayo Clinic in Florida. Their study suggests other forms of cancer may also be driven by this gene, matrix metalloproteinase-10 (MMP-10).
The study, published in the journal PLoS ONE on April 24, shows that MMP-10 is a growth factor secreted and then used by cancer stem-like cells to keep themselves vital. These cells then drive lung cancer and its spread, and are notoriously immune to conventional ...
Guidelines for prostate screening widely ignored
2012-04-25
New research confirms that the controversial decision by Warren Buffet – the 81-year-old CEO of Berkshire Hathaway – to undergo a blood test screening for prostate cancer despite his age is hardly unusual. Despite recommendations in 2008 from the United States Preventive Services Task Force against testing for prostate cancer in men aged 75 years or older, almost half of men in that age group continue to get screening tests.
In 2005, before the recommendations were released, 43 percent of men age 75 and above elected to take the prostate-specific antigen (PSA) test. In ...
Connecting cilia: Cellular antennae help cells stick together
2012-04-25
Primary cilia are hair-like structures which protrude from almost all mammalian cells. They are thought to be sensory and involved in sampling the cell's environment. New research, published in BioMed Central's open access journal Cilia, launched today, shows that cilia on cells in the retina and liver are able to make stable connections with each other - indicating that cilia not only are able to sense their environment but are also involved in cell communication.
Primary cilia are structurally and functionally very similar to eukaryotic flagella (motile tails used to ...
Discerning males remain faithful
2012-04-25
Discerning males remain faithful
...if you are a spider. Sex for male orb web spiders (Argiope bruennichi) is a two shot affair since the act of mating destroys their genitalia. If they survive being eaten during their first encounter with a female, they have two choices – to mate again with the same female (monogynous) or try to find a new partner (bigynous). New research published in BioMed Central's open access journal Frontiers in Zoology shows that choice of mating behavior for A. bruennichi depends on the size and age of the first female they mate with.
Monogamous ...